Non-invasive screening tests

Multiple Pregnancy: Epidemiology, Gestation, and Perinatal Outcome

Volumn , Issue , 2005, Pages 368-384

  Spencer, K ^a  

^a HAROLD WOOD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85145247386     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (136)

1. Oliviennes F, Kadhel P, Rufat P, et al. Perinatal outcome of twin pregnancies obtained after in vitro fertilization: comparison with twin pregnancies obtained spontaneously or after ovarian stimulation. Fertil Steril 1996;66:105-9.
2. Spencer K, Salonen R, Muller F. Down's syndrome screening in multiple pregnancies using a-fetoprotein and free P-hCG. Prenat Diagn 1994;14:537-42.
3. Office of National Statistics. 1999 Birth Statistics England & Wales. Series FM1, No 28. London: Stationery Office, 2000.
4. Myrianthopoulos NC. Congenital malformations: the contribution of twin studies. Birth Defects Orig Artic Ser 1978; 14:151-65.
5. Doyle Pe, Beral, Botting B, Wale CJ. Congenital malformations in twins in England and Wales. J Epidemiol Community Health 1990;45:43-8.
6. Baldwin VJ. Anomalous development of twins. In Baldwin VJ, ed. Pathology of Multiple Pregnancies. New York: Springer-Verlag, 1994:169-97.
7. Rodis JF, Egan JFX, Craffey A, et al. Calculated risk of chromosomal abnormalities in twin gestations. Obstet Gynecol 1990;76:1037-41.
8. Cuckle H. Down's syndrome screening in twins. J Med Screen 1998;5:3-4.
9. Ghidini A, Lynch L, Hicks C, et al. The risk of second trimester amniocentesis in twin gestations: a case control study. Am J Obstet Gynecol 1993;169:1013-16.
10. Kidd SA, Lancaster PAL, Anderson JC, et al. A cohort study of pregnancy outcome after amniocentesis in twin pregnancy. Paediatr Perinat Epidemiol 1997;11:200-13.
11. De Catte L, Liebaers I, Foulon W, et al. First trimester chorionic villus sampling in twin gestations. Am J Perinatol 1996; 13:413-17.
12. Wapner RJ, Johnson A, Davis G, et al. Prenatal diagnosis in twin gestations: a comparison between second trimester amniocentesis and first trimester chorionic villus sampling. Obstet Gynecol 1993;82:49-56.
13. Sebire NJ, Noble PL, Psarra A, et al. Fetal karyotyping in twin pregnancies: selection of technique by measurement of fetal nuchal translucency. Br J Obstet Gynaecol 1996;103:887-90.
14. Reynolds TM. Down's syndrome screening in twin pregnancies. Prenat Diagn 1995;15:386-7.
15. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. Health Technol Assess 1998;2(1).
16. Brock DJH, Sutcliffe RG. Alphafetoprotein in the antenatal diagnosis of anencephaly and spina bifida. Lancet 1972;2: 197-9.
17. Hino M, Koki Y, Nishi S. Nimpu ketsu naka no a-fetoprotein. Igaku No Ayumi 1972;82:512-13.
18. Wald NJ, Brock DJH, Bonnar J. Prenatal diagnosis of spina bifida and anencephaly by serum a-fetoprotein measurement. Lancet 1974;1:765-7.
19. Brock DJH, Bolton AE, Scrimgeour JB. Prenatal diagnosis of spina bifida and anencephaly through maternal plasma a-fetoprotein measurement. Lancei 1974;1:767-9.
20. Report of the UK Collaborative Study of a-Fetoprotein in Relation to Neural Tube Defects. Maternal serum a-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Lancei 1977; 1:1323-32.
21. Second report of the UK Collaborative Study on a-Fetoprotein in Relation to Neural Tube Defects. Amniotic fluid a-fetoprotein measurement in antenatal diagnosis of anencephaly and open spina bifida in early pregnancy. Lancei 1979;2:652-62.
22. Smith AD, Wald NJ, Cuckle HS, et al. Amniotic fluid acetylcholinesterase as a possible diagnostic test for neural tube defects in early pregnancy. Lancei 1979;2:685-8.
23. Report of the Collaborative Acetylcholinesterase Study. Amniotic fluid acetylcholinesterase electrophoresis as a secondary test in the diagnosis of anencephaly and open spina bifida in early pregnancy. Lancei 1981;2:321-4.
24. Second report of the Collaborative Acetylcholinesterase Study. Amniotic fluid acetylcholinesterase measurement in the prenatal diagnosis of open neural tube defects. Prenai Diagn 1989;9:813-29.
25. Johnson SP, Sebire NJ, Snijders RJ, et al. Ultrasound screening for anencephaly at 10-14 weeks of gestation. Ultrasound Obsiei Gynecol 1997;9:14-16.
26. Chatzipapas IK, Whitlow BJ, Economides DL. The 'Mickey Mouse' sign and the diagnosis of anencephaly in early pregnancy. Ultrasound Obstet Gynecol 1999;13:196-9.
27. Nicolaides KH, Campbell S, Gabbe SG, Guidette R. Ultrasound screening for spina bifida: cranial and cerebellar signs. Lancei 1986;2:72-4.
28. Blumefield Z, Siegler E, Bronshtein M. The early diagnosis of neural tube defects. Prenai Diagn 1993;13:863-71.
29. Sebire NJ, Noble PL, Thorpe-Beeston JG, et al. Presence of the 'lemon' sign in fetuses with spina bifida at the 10-14 week scan. Ultrasound Obstet Gynecol 1997;10:403-5.
30. Lennon CA, Gray DL. Sensitivity and specificity of ultrasound for the detection of neural tube and ventral wall defects in a high risk population. Obsiei Gynecol 1999;94:562-6.
31. Aitken DA, McCaw G, Crossley JA, et al. First trimester screening for fetal chromosome abnormalities and neural tube defects. Prenai Diagn 1993;13:681-9.
32. Sebire NJ, Spencer K, Noble PL, et al. Maternal serum a-fetoprotein in fetal neural tube and abdominal wall defects at 10 to 14 weeks of gestation. Br J Obsiei Gynaecol 1997;104: 849-51.
33. Thom H, Buckland CM, Campbell AGM, et al. Maternal serum alphafetoprotein in monozygotic and dizygotic twin pregnancies. Prenai Diagn 1984;4:341-6.
34. Muller F, Dreux S, Dupoizat H, et al. Second trimester Down syndrome maternal serum screening in twin pregnancies: impact of chorionicity. Prenai Diagn 2003;23:331-5.
35. Crossley JA. Biochemical screening for fetal chromosome abnormaliiies. PhD Thesis, University of Glasgow, 1993.
36. Raty R, Virtanen A, Koskinen P, et al. Maternal midtrimester serum AFP and free p hCG levels in in viro fertilization twin pregnancies. Prenai Diagn 2000;20:221-3.
37. O'Brien JE, Dvorin E, Yaron Y, et al. Differential increases in AFP, hCG and uE3 in twin pregnancies: impact on attempts to quantify Down syndrome screening calculations. Am J Med Genei 1997;73:109-12.
38. Barnabei V, Krantz DA, Macri JN, Larsen JW. Enhanced twin pregnancy detection within an open neural tube defect and Down syndrome screening protocol using free p hCG and AFP. Prenai Diagn 1995;15:1131-4.
39. Wald NJ, Cuckle HS, Peck S, et al. Maternal serum a-fetoprotein in relation to zygosity. Br Med J 1979;1:455-7.
40. Aitken DA. Biochemical screening in twins. In Ward RH, Whittle M, eds. Muliiple Pregnancy. London: RCOG Press, 1995:171-85.
41. Drugan A, Sokol RJ, Ager FN, et al. Clinical implications of amniotic fluid a fetoprotein in twin pregnancy. J Reprod Med 1989;34:977-80.
42. Ghosh A, Woo JSK, Rawlinson HA, et al. Prognostic significance of raised serum a-fetoprotein levels in twin pregnancies. Br J Obsiei Gynaecol 1982;89:817-20.
43. Cuckle HS, Wald NJ, Stevenson JD, et al. Maternal serum a-fetoprotein screening for open neural tube defects in twin pregnancies. Prenai Diagn 1990;10:71-7.
44. Hook EB. Prevalence, risks and recurrence. In Brock DJH, Rodeck CH, Ferguson-Smith MA, eds. Prenatal Diagnosis and Screening. Edinburgh: Churchill Livingstone, 1992:351-92.
45. Egan JF, Benn P, Borgida AF, et al. Efficacy of screening for fetal Down syndrome in the United States from 1974 to 1997. Obsiei Gynecol 2000;96:979-85.
46. Cuckle HS, Wald NJ, Thomson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alphafetoprotein level. Br J Obsiei Gynaecol 1987;94:387-402.
47. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum a-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984; 148:886-94.
48. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum a-fetoprotein measurements: a screening test for Down's syndrome. Lancei 1984;1: 926-9.
49. Spencer K, Carpenter P. Screening for Down's syndrome using serum a fetoprotein: a retrospective study indicating caution. Br Med J 1985;290:1940-3.
50. Aitken DA, Crossley JA, Spencer K. Prenatal screening for neural tube defects and aneuploidy. In Rimoin DL, Connor JM, Pyeritz RE, Korf BR, eds. Emery & Rimoin' Principles and Praciice of Medical Geneiics. London: Churchill Livingstone, 2002;1:763-801.
51. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenai Diagn 1987;7:623-30.
52. Macri JN, Kasturi RV, Krantz DA, et al. Maternal serum Down syndrome screening: free p protein is a more effective marker than human chorionic gonadotropin. Am J Obsiei Gynecol 1990;163:1248-53.
53. Spencer K. Evaluation of an assay of the free p-subunit of choriogonadotropin and its potential value in screening for Down's syndrome. Clin Chem 1991;37:809-14.
54. Spencer K, Coombes EJ, Mallard AS, Ward AM. Free p human choriogonadotropin in Down syndrome screening: a multicentre study of its role compared with other markers. Ann Clin Biochem 1992;29:506-18.
55. Spencer K, Mallard AS, Coombes EJ, Macri JN. Prenatal screening for trisomy 18 with free p human chorionic gonadotrophin as a marker. Br Med J 1993;307:1455-8.
56. Canick JA, Knight GJ, Palomaki GE, et al. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obsiei Gynaecol 1988;95: 330-3.
57. Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum unconjugated oestriol as an antenatal screening tests for Down's syndrome. Br J Obsiei Gynaecol 1988;95:334-41.
58. Reynolds T, John R. A comparison of unconjugated oestriol assay kits shows that the expression of results as multiple of the median causes unacceptable variation in calculated Down syndrome risk factors. Clin Chem 1992;38:1888-93.
59. Crossley JA, Aitken DA, Connor JM. Second trimester unconjugated oestriol in maternal serum from chromosomally abnormal pregnancies using an optimised assay. Prenat Diagn 1993;13:271-80.
60. Spencer K. Is the measurement of unconjugated oestriol of value in screening for Down's syndrome. In Grudzinskas JG, Chard T, Chapman M, Cuckle H, eds. Screening for Dow/n, s Syndrome. Cambridge: Cambridge University Press, 1994: 141-61.
61. Van Lith JMM, Pratt JJ, Beekhuis JR, Mantingh A. Second trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome. Prenat Diagn 1992;12:801-6.
62. Spencer K, Wood PJ, Anthony FW. Elevated levels of maternal serum inhibin immunoreactivity in second trimester pregnancies affected by Down's syndrome. Ann Clin Biochem 1993;30:219-20.
63. Wallace EM, Crossley JA, Ritoe SC, et ah. Evolution of an inhibin-A ELISA method: implications for Down's syndrome screening. Ann Clin Biochem 1998;35:656-64.
64. Sturgeon CM, Ellis AR, Al-Sadie R, Logan M. UKNEQASfor peptide hormones and related substances. Annuah Review 2002. Edinburgh: UKNEQAS, 2003:72-3.
65. Spencer K, Souter V, Tul N, et al. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free p-human chorionic gonadotropin and pregnancy associated plasma protein-A. Uhtrasound Obstet Gynecol 1999;13:231-7.
66. Spencer K, Ong C, Skentou H, et al. Screening for trisomy 13 by fetal nuchal translucency thickness and maternal serum free p-hCG and PAPP-A at 10-14 weeks. Prenat Diagn 2000;20:411-16.
67. Tul N, Spencer K, Noble P, et al. Screening for trisomy 18 by fetal nuchal translucency, maternal serum free p-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 1999;19: 1035-42.
68. Spencer K, Berry E, Crossley JA, et al. Is maternal serum total hCG a marker of trisomy 21 in the first trimester of pregnancy? Prenat Diagn 2000;20:311-17.
69. Spencer K, Heath V, Flack N, et al. First trimester maternal serum AFP and total hCG in aneuploides other than trisomy 21. Prenat Diagn 2000;20:635-9.
70. Spencer K, Nicolaides KH. A first trimester trisomy 13/ trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free p-hCG and PAPP-A. Prenat Diagn 2002;22:877-9.
71. Spencer K, Crossley JA, Aitken DA, et al. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2002;39:567-76.
72. Spencer K, Crossley JA, Aitken DA, et al. The effect of temporal variation of biochemical markers of trisomy 21 across the first and second trimester of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome. Ann Clin Biochem 2003;40:219-31.
73. Spencer K, Crossley JA, Green K, et al. Second trimester levels of pregnancy associated plasma protein-A in cases of trisomy 18. Prenat Diagn 1999;19:1127-34.
74. Nicolaides KH, Azar G, Byrne D, et al. Fetal nuchal translucency: ultrasound screening for chromosome defects in the first trimester of pregnancy. Br Med J 1992;304: 867-9.
75. Pandya PP, Snijders RJM, Johnson SP, et al. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Br J Obstet Gynaecol 1995;102:957-62.
76. Nicolaides KH, Sebire NJ, Snijders RJM. The 11-14 Weeks Scan. The Diagnosis of Fetal Abnormalities. Carnforth, UK: Parthenon Publishing, 1999.
77. Reynolds T, Penney M. The mathematical basis of multivariate risk analysis: with special reference to screening for Down's syndrome associated pregnancy. Ann Clin Biochem 1990;27: 452-8.
78. Cuckle H. Time for total shift to first trimester Down's screening. Lancet 2001;358:1658-9.
79. Barkai G, Goldman B, Ries L, et al. Expanding multiple marker screening for Down's syndrome to include Edwards' syndrome. Prenat Diagn 1993;13:843-50.
80. Palomaki GE, Haddow JE, Knight GJ, et al. Risk based prenatal screening for trisomy 18 using a-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. Prenat Diagn 1995;5:713-23.
81. Muller F, Sault C, Lemay C, et al., and the ABA Collaborative Group. Second trimester two-step trisomy 18 screening using maternal serum markers. Prenat Diagn 2002;22:605-8.
82. Spencer K. Second trimester prenatal screening for Down's syndrome using a-fetoprotein and free p hCG: a seven year review. Br J Obstet Gynaecol 1999;106:1287-93.
83. Muller F, Forestier F, Dingeon B, and the ABA Study Group. Second trimester trisomy 21 maternal serum marker screening. Results of a country wide study of 854 902 patients. Prenat Diagn 2002;22:925-9.
84. Cuckle H. Biochemical screening for Down syndrome. Eur J Obstet Gynecol Reprod Biol 2000;92:97-101.
85. Wald NJ, Huttly WJ, Hackshaw AK. Antenatal screening for Down's syndrome with the quadruple test. Lancet 2003; 361:835-6.
86. Snijders RJM, Noble P, Sebire N, et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 1998;351:343-6.
87. Nicolaides KH. Screening for chromosomal defects. Ultrasound Obstet Gynecol 2003;21:313-21.
88. Bewley S, Roberts LJ, Mackinson M, Rodeck C. First trimester fetal nuchal translucency: problems with screening the general population. II. Br J Obstet Gynaecol 1995;102:386-8.
89. Kornman LH, Morssink LP, Beekhuis JR, et al. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine practice. Prenat Diagn 1996;16:797-805.
90. Haddow JE, Palomaki GE, Knight GJ, et al. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 1998;338:955-61.
91. Crossley JA, Aitken DA, Cameron AD, et al. Combined ultrasound and biochemical (CUB) screening for Down's syndrome in the first trimester: a Scottish multicentre study. Br J Obstet Gynaecol 2002;109:667-76.
92. Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURRUS). Health TechnolAssess 2003;7(11).
93. Spencer K, Aitken DA, Crossley JA, et al. First trimester biochemistry screening for trisomy 21: the role of free p hCG, a fetoprotein and pregnancy associated plasma protein-A. Ann Clin Biochem 1994;31:447-54.
94. Wald NJ, George L, Smith D, et al. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynaecol 1996;103:407-12.
95. Krantz DA, Larsen JW, Buchanan PD, Macri JN. First trimester Down syndrome screening: free p human chorionic gonadotropin and pregnancy associated plasma protein-A. Am J Obstet Gynecol 1996;174:612-16.
96. Berry E, Aitken DA, Crossley JA, et al. Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimester. Br J Obstet Gynaecol 1997;104:811-17.
97. Cuckle HS, van Lith JMM. Appropriate biochemical parameters in first trimester screening for Down syndrome. Prenat Diagn 1999;19:505-12.
98. Dunstan FDJ, Nix ABJ. Screening for Down's syndrome: the effect of test date on the detection rate. Ann Clin Biochem 1998;35:57-61.
99. Morris JK, Wald NJ, Watt HC. Fetal loss in Down's syndrome pregnancies. Prenat Diagn 1999;19:142-5.
100. Spencer K. What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence when first trimester detection rates are superior to those in the second trimester? Prenat Diagn 2001;21:788-9.
101. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first trimester screening for Down's syndrome. Prenat Diagn 1997;17:821-9.
102. De Graff IM, Pajkrt E, Bilardo CM, et al. Early pregnancy screening of fetal aneuploidy with serum markers and nuchal translucency. Prenat Diagn 1999;19:458-62.
103. Spencer K, Tul N, Nicolaides KH. Maternal serum free P hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn 2000;20:390-4.
104. Spencer K, Liao AWJ, Skentou H, et al. Screening for triploidy by fetal nuchal translucency and maternal serum free p-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 2000;20:852-3.
105. Spencer K. Point of care screening for chromosomal anomalies in the first trimester of pregnancy. Clin Chem 2002; 48:403-4.
106. Spencer K, Spencer CE, Power M, et al. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol 2000;107:1271-5.
107. Spencer K, Spencer CE, Power M, et al. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one stop clinic: a review of three years' prospective experience. Br J Obstet Gynaecol 2003:110;281-6.
108. Bindra R, Heath V, Liao A, et al. One stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 2002; 20:219-25.
109. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med 1999;341:461-7.
110. Copel JA, Bahado-Singh RO. Prenatal screening for Down's syndrome-a search for the family's view. N Engl J Med 1999;341:521-2.
111. Reynolds T, Zimmerman R, Wright E. Integrated screening for Down syndrome. N Engl J Med 1999;341:1935.
112. Integrated test. Down's Screening News 2000;7:28-9.
113. Cicero S, Curcio P, Papageorghiou A, et al. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 2001;358:1665-7.
114. Sonek J. Nasal bone evaluation with ultrasonography: a marker for fetal aneuploidy. Ultrasound Obstet Gynecol 2003; 22:11-15.
115. Cicero S, Longo D, Rembouskos G, et al. Absent nasal bone at 11-14 weeks of gestation and chromosomal defects. Ultrasound Obstet Gynecol 2003;22:31-5.
116. Cicero S, Dezerega V, Andrade E, et al. Learning curve for sonographic examination of the fetal nasal bone at 11-14 weeks. Ultrasound Obstet Gynecol 2003;22:135-7.
117. Cicero S, Bindra R, Rembouskos G, et al. Integrated ultrasound and biochemical screening for trisomy 21 at 11-14 weeks. Prenat Diagn 2003;23:306-10.
118. Spencer K. Age related detection and false positive rates when screening for Down's syndrome in the first trimester using nuchal translucency and maternal serum free p-hCG and PAPP-A. Br J Obstet Gynecol 2001;108:1043-6.
119. Meyers C, Adam R, Dungan J, Prenger V. Aneuploidy in twin gestations: when is maternal age advanced? Obstet Gynecol 1997;89:248-51.
120. Wald NJ, Cuckle HS, Wu T, George L. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. Br J Obstet Gynaecol 1991;8:905-8.
121. Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester using free p-hCG and PAPP-A, combined with fetal nuchal translucency thickness. Prenat Diagn 2000;20:91-5.
122. Niemimaa M, Suonpaa M, Heinonen S, et al. Maternal serum human chorionic gonadotrophin and pregnancy associated plasma protein-A in twin pregnancies in the first trimester. Prenat Diagn 2002;22:183-5.
123. Orlandi F, Rossi C, Allegra A, et al. First trimester screening with free p-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. Prenat Diagn 2002;22:718-21.
124. Brambati B, Macri JN, Tului L, et al. First trimester aneuploidy screening: maternal serum PAPP-A and free p-hCG. In Grudzinskas JG, Ward RHT, eds. Screening for Down Syndrome in the First Trimester. London: RCOG Press, 1997:135-47.
125. Noble PL, Snijders RJ, Abraha HD, et al. Maternal serum free p-hCG at 10-14 weeks of gestation in trisomic twin pregnancies. Br J Obstet Gynaecol 1997;104:741-3.
126. Bersinger NA, Noble P, Nicolaides KH. First trimester maternal serum PAPP-A, SP1 and M-CF levels in normal and trisomic twin pregnancies. Prenat Diagn 2003;23:157-62.
127. Spencer K, Nicolaides KH. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one stop clinic: a review of three years' experience. Br J Obstet Gynaecol 2003;110:276-80.
128. Spencer K, Salonen R, Muller F. Down's syndrome screening in multiple pregnancies using a-fetoprotein and free p hCG. Prenat Diagn 1994;14:537-42.
129. Neveux LM, Palomaki GE, Knight GJ, Haddow JE. Multiple marker screening for Down syndrome in twin pregnancies. Prenat Diagn 1996;16:29-35.
130. Verdin SM, Braithwaite JM, Spencer K, Economides DL. Prenatal diagnosis of trisomy 21 in monozygotic twins with increased nuchal translucency and abnormal serum biochemistry. Fetal Diagn Ther 1997;12:153-5.
131. Pandya PP, Hilber F, Snijders RJM, et al. Nuchal translucency thickness, crown rump length in twin pregnancies with chromosomally normal fetuses. J Ultrasound Med 1995;14:565-8.
132. Sebire NJ, Snijders RJM, Hughes K, et al. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Br J Obstet Gynaecol 1996;103:999-1003.
133. Sebire NJ, Noble PL, Psarra A, et al. Fetal karyotyping in twin pregnancies: selection of technique by measurement of fetal nuchal translucency. Br J Obstet Gynaecol 1996;103:887-90.
134. Spencer K, Nicolaides KH. First trimester prenatal diagnosis of trisomy 21 in discordant twins using fetal nuchal translucency thickness and maternal serum free p-hCG and PAPP-A. Prenat Diagn 2000;20:683-4.
135. Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester: does chorionicity impact on maternal serum free p-hCG or PAPP-A levels? Prenat Diagn 2001; 21:715-17.
136. Wald NJ, Rish S, Hackshaw AK. Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies. Prenat Diagn 2003;23:588-92.